Paper - WANFANG MED ONLINE

You Position: Home > Paper

Optimizing prevention of contrast-induced acute kidney injury in type 2 diabetic patients with at least moderate renal impairment

( views:192, downloads:0 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 19

DOI:: 10.3760/cma.j.issn.0366-6999.2012.19.001

Key Word:: acute kidney injury;contrast-induced;type 2 diabetic patients

Abstract： Diabetes is a key risk factor for chronic kidney disease,1 and patients with type 2 diabetes and coronary artery disease are at high risk of cardiovascular events particularly when renal function is impaired.2-4 Decision on how and when to proceed to coronary revascularization in an individual type 2 diabetic patient should be based on the extent of coronary disease,ischemic burden, ventricular function, as well as co-morbidities (e.g., renal insufficiency).

Reference

[1]SHEN Wei-feng.Improving long-term outcomes of coronary intervention in patients with diabetes[J].2009,(6).
[2]ZHANG Rui-yan,NI Jing-wei,ZHANG Jian-sheng,etc.Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention[J].2006,(14).
[3]FU Xiang-hua,FAN Wei-ze,GU Xin-shun,etc.Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction[J].2007,(14).
[4]DOU Ke-fei,XU Bo,YANG Yue-jin,etc.Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry[J].2009,(6).
[5]WANG Xue-chao,FU Xiang-hua,WANG Yan-bo,etc.Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate[J].2011,(6).
[6]WANG Yan-bo,FU Xiang-hua,GU Xin-shun,etc.Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome[J].2012,(6).
[7]LI Jian-hua,HE Neng-shu.Prevention of iodinated contrast-induced nephropathy[J].2011,(23).
[8]GENG Wei,FU Xiang-hua,GU Xin-shun,etc.Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty[J].2012,(19).
[9]Harold L, Dauerman.In search of an algorithm to prevent acute kidney injury.[J].2009,2(11).
[10]Dauerman HL,Solomon R.Contrast-induced acute kidney injury.[J].2010,122(23).
[11]F N, Ziyadeh,M P, Cohen.Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy.[J].1993,125(1).
[12]Cohen MP,Chen S,Shea E,etc.Glycated albumin increases oxidative stress, activates NF-kappaB and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta1 production in macrophage RAW cells.[J].2003,141(4).
[13]Er,F.,Nia,A.M.,Dopp,H.,etc.Ischemic preconditioning for prevention of contrast medium-induced nephropathy: Randomized pilot renpro trial (Renal protection trial)[J].2012,126(3).
[14]Oberg BP,McMenamin E,Lucas FL,etc.Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.[J].2004,65(3).
[15]Hu J,Yang ZK,Zhang Q,etc.Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study.[J].2009,112(3).
[16]McCullough PA.Contrast-induced acute kidney injury.[J].2008,51(15).
[17]Palevsky PM,Weisbord SD.Strategies for the prevention of contrast-induced acute kidney injury.[J].2010,19(6).
[18]Yao-Min Hung,Shoa-Lin Lin,Shih-Yuan Hung,etc.Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography[J].2012,(5).
[19]Musilli,N.,Leoncini,M.,Gallopin,M.,etc.Persistent renal damage after contrast-induced acute kidney injury: Incidence, evolution, risk factors, and prognosis[J].2012,125(25).
[20]Bonventre,J.V..Limb ischemia protects against contrast-induced nephropathy[J].2012,126(4).
[21]Lin Lu,Wen-hui PENG,Wei Wang,etc.Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats[J].2011,(8).
[22]Murphy,S.A.,Swahn,E.,Braunwald,E.,etc.An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials[J].2012,60(2).
[23]Maddox TM,Stolker JM,Rao S,etc.Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.[J].2010,55(14).
[24]Angiolillo DJ,Bernardo E,Capodanno D,etc.Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.[J].2010,55(11).
[25]Angiolillo DJ,Roffi M,Kappetein AP.Current concepts on coronary revascularization in diabetic patients.[J].2011,32(22).
[26]Tapuria N,Seifalian AM,Kumar Y,etc.Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review.[J].2008,150(2).
[27]Meigs JB,Levy D,Leip EP,etc.Glycemic status and development of kidney disease: the framingham heart study.[J].2005,28(10).